Biomeostasis

What Biomeostasis does

Biomeostasis (legal entity SAS BIOMEOSTASIS, share capital €50,000) is a privately held Contract Research Organization founded in 2010 in Marseille, France by Bruno Bariohay, Ph.D. and Julien Roux, Ph.D. The company provides bespoke preclinical in vivo pharmacology services that assess the efficacy and mechanism of action of health products in rodent models across three therapeutic verticals: metabolic diseases (obesity, diabetes, MASLD/MASH, atherosclerosis, binge-eating), gastrointestinal disorders (constipation, inflammatory bowel disease), and muscle-wasting conditions (sarcopenia, cachexia, Duchenne muscular dystrophy). Service delivery relies on a catalog of established and validated rodent models (e.g., ob/ob and db/db mice, ZDF and NOD rats, DIO and STZ-DIO models, ApoE atherosclerosis models, DSS/TNBS colitis models, mdx B10.MDX and D2.MDX DMD models, and C26/Lewis Lung carcinoma cachexia models) combined with gold-standard physiological, biochemical and biomarker readouts executed in a 500 m2 dedicated laboratory and EOPS animal facility near Marseille.

The business is a project-based professional services CRO: it sells tailor-made preclinical efficacy studies to pharmaceutical, biotechnology and agrofood clients and generates revenue through contracted study fees (no public pricing; project-based and customized). Go-to-market is sales-led and direct (B2B enterprise), driven by the corporate website, peer-reviewed publications and inbound contacts, with named repeat customers such as Søren Ljungberg Pedersen (CTO & Head of Research), Olivier Bezy (Senior Director, Exploratory), Yuriy Kirichok (Co-founder/CSO), Andreas Höglund (Principal Scientist) and Jim Smeeding (Co-founder/President) providing public testimonials. Operationally, Biomeostasis runs on a lean model of 1-10 employees structured around two co-founder executives (CEO and CSO) and four Ph.D. Senior Project Leaders with deep domain expertise, supported by the Marseille EOPS facility operational since 2018. No external institutional investors, M&A activity, patents, strategic partnerships or AI-driven product capabilities are disclosed; the firm is GDPR-compliant and remains founder-controlled.

Name

Biomeostasis

Legal name

SAS BIOMEOSTASIS

Website

https://biomeostasis.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Short description

Biomeostasis is a privately held Marseille-based Contract Research Organization providing bespoke preclinical in vivo efficacy studies in rodent models for metabolic diseases, GI disorders, and muscle-wasting conditions to pharmaceutical, biotech, and agrofood clients.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

In Vivo Pharmacology (Efficacy/PD Models) (HLAGAFAA)

akta.pro secondary industries

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Preclinical contract research
• In vivo pharmacology services
• Rodent disease models
• Metabolic disease research
• Drug efficacy studies

Headquarters

HQ city

Marseille

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Research Services: Preclinical in vivo efficacy studies contracted by pharmaceutical, biotech and agrofood companies. Services include model development, study execution, and data analysis on metabolic diseases, GI disorders and muscle-wasting conditions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Biomeostasis is a Contract Research Organization (CRO) that delivers tailor-made preclinical in vivo efficacy studies using rodent models for pharmaceutical, biotech and agrofood clients. The company assesses the efficacy and mechanisms of action of health products across three therapeutic areas — Metabolic Diseases (obesity, diabetes, MASLD/MASH, atherosclerosis, binge-eating), GI Disorders (constipation, IBD), and Muscle-Wasting Conditions (sarcopenia, cachexia, DMD). Services span model development, study execution, biomarker analysis and data reporting, supported by a 500m2 EOPS animal facility near Marseille.

Product overview

Biomeostasis offers a unified suite of in vivo pharmacology services focused on preclinical efficacy and mechanism of action studies for health products. Their core offering consists of disease-specific rodent model studies across three therapeutic areas: Metabolic Diseases (obesity, diabetes, MASLD/MASH, atherosclerosis, binge-eating), GI Disorders (constipation, IBD), and Muscle-Wasting Conditions (sarcopenia, cachexia, DMD). Each service area utilizes established and validated rodent models combined with gold-standard methodological assessments to provide pharmaceutical, biotech, and agrofood companies with high-added value data on compound efficacy.

Differentiator

Problem solved

Functional benefit

Products and services

• In Vivo Pharmacology Services (Preclinical CRO Services) Tailor-made preclinical in vivo efficacy and mechanism-of-action studies in rodent models, covering model development, study execution, biomarker analysis and data reporting for pharmaceutical, biotech and agrofood clients across Metabolic Diseases, GI Disorders and Muscle-Wasting Conditions.
• Obesity Models and Studies Established and validated rodent models of overweight and obesity including nutritional models (overweight mouse models) and genetic models (ob/ob and db/db mice), used for chronic efficacy and mechanism-of-action studies of anti-obesity compounds.
• Diabetes Models and Studies Preclinical diabetes studies using Type-1 and Type-2 diabetes rodent models, including induced models (prediabetic, DIO, STZ-induced) and genetic models (db/db mice, ZDF rats, NOD mice), with gold-standard methods for efficacy assessment.
• MASLD/MASH Models and Studies Preclinical studies on metabolic dysfunction-associated liver diseases (MASLD/MASH) using nutritional models (DIO MASLD, DIO MASH, STZ-DIO mouse models) for chronic efficacy and mechanism-of-action studies.
• Atherosclerosis Models and Studies Established rodent models of atherosclerosis, including genetic models (ApoE mice) and induced models (ApoE mice on High Fat Diet), used for chronic efficacy and mechanism-of-action studies.
• Binge-Eating Models and Studies Intermittent access model of binge eating in female rats for chronic efficacy and mechanism-of-action studies of compounds addressing binge-eating disorder.
• Constipation Models and Studies Subacute constipation model in rats induced by repetitive administration of loperamide for chronic efficacy and mechanism-of-action studies of compounds targeting GI motility disorders.
• IBD Models and Studies Mouse models of Ulcerative Colitis (DSS-induced colitis) and rat model of Crohn's Disease (TNBS-induced) for efficacy and mechanism-of-action studies of inflammatory bowel disease compounds.
• Sarcopenia Models and Studies Ageing models for sarcopenia research including sarcopenia mouse model, sarcopenic obesity mouse model, and sarcopenia rat model for chronic efficacy studies of muscle-wasting interventions.
• Cachexia Models and Studies Cancer cachexia mouse models induced by subcutaneous inoculation of Lewis Lung carcinoma or C26 cells for efficacy and mechanism-of-action studies of cachexia compounds.
• DMD Models and Studies Extensively characterized mdx mouse models (B10.MDX, D2.MDX) that recapitulate Duchenne muscular dystrophy features for preclinical compound assessment.

Quantifiable outcome

• 350+ in vivo preclinical projects completed
• +2 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Pharmaron: Pharmaron is a global CRO/CDMO offering preclinical in vivo pharmacology, safety assessment, and integrated drug discovery services — a broader incumbent that competes for preclinical CRO budgets in the same therapeutic areas as Biomeostasis.
• Labcorp Drug Development (Covance): Labcorp (including its Covance preclinical business) is a top-tier global CRO with extensive early-stage discovery and preclinical capabilities including metabolic and specialty disease rodent studies — a broad incumbent that competes for the same pharma/biotech R&D budgets.
• Eurofins Discovery: Eurofins Discovery offers a broad portfolio of preclinical research services including in vivo pharmacology and disease models — overlapping with Biomeostasis in metabolic and inflammatory disease rodent studies as part of a much wider discovery services portfolio.
• Inotiv: Inotiv is a US-based preclinical CRO/CDMO offering research models, in vivo efficacy, safety, and toxicology services — comparable in providing rodent study services to pharma/biotech but with broader capabilities and larger scale.
• WuXi AppTec: WuXi AppTec provides comprehensive preclinical and clinical CRO/CDMO services including in vivo pharmacology — competes with Biomeostasis for global pharma preclinical study outsourcing with significantly larger scale and integrated service offerings.
• Charles River Laboratories: Charles River is a large global CRO offering preclinical in vivo pharmacology, safety assessment, and research models services — overlaps with Biomeostasis's rodent efficacy study offering as part of a much broader portfolio of preclinical and manufacturing services.

Direct peers

• Gubra: Gubra is a Danish preclinical CRO specialized in metabolic diseases (obesity, diabetes, MASH/NASH) and peptide drug discovery — directly overlapping with Biomeostasis's core metabolic and GI disease model offerings. Both serve pharma/biotech with rodent efficacy studies in similar therapeutic areas.
• Crown Bioscience: Crown Bioscience is a global preclinical CRO with significant metabolic disease, oncology, and inflammatory disease rodent model offerings — comparable to Biomeostasis in the metabolic disease in vivo pharmacology niche, but at much larger scale.
• Physiogenex: Physiogenex is a French preclinical CRO offering rodent models in metabolic diseases (obesity, diabetes, NASH), cardiovascular and renal diseases — directly comparable to Biomeostasis on geography, size, therapeutic focus, and customer base.

Emerging players

• Biocytogen: Biocytogen is a Chinese preclinical CRO with rodent model development, efficacy, and mechanistic study services — comparable to Biomeostasis in offering rodent efficacy studies to pharma/biotech, with growing overlap in metabolic and inflammatory disease areas.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/biomeostasis

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biomeostasis